338 related articles for article (PubMed ID: 29935311)
1. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
[TBL] [Abstract][Full Text] [Related]
2. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
[TBL] [Abstract][Full Text] [Related]
3. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data.
Tkachev V; Sorokin M; Garazha A; Borisov N; Buzdin A
Methods Mol Biol; 2020; 2063():235-255. PubMed ID: 31667774
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
5. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data.
Buzdin AA; Prassolov V; Zhavoronkov AA; Borisov NM
Methods Mol Biol; 2017; 1613():53-83. PubMed ID: 28849558
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
8. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
10. [Individualization of anticancer therapy; molecular targets of novel drugs in oncology].
Regulska K; Stanisz B; Regulski M
Postepy Hig Med Dosw (Online); 2012 Nov; 66():855-67. PubMed ID: 23175342
[TBL] [Abstract][Full Text] [Related]
11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
12. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
13. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Wijdeven RH; Pang B; Assaraf YG; Neefjes J
Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
[TBL] [Abstract][Full Text] [Related]
14. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
[TBL] [Abstract][Full Text] [Related]
15. Paul Workman: Drugging the Cancer Genome.
Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
[No Abstract] [Full Text] [Related]
16. Understanding the Cause and Consequence of Tumor Heterogeneity.
Khatib S; Pomyen Y; Dang H; Wang XW
Trends Cancer; 2020 Apr; 6(4):267-271. PubMed ID: 32209440
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
18. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
20. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
Le Tourneau C; Kamal M; Tsimberidou AM; Bedard P; Pierron G; Callens C; Rouleau E; Vincent-Salomon A; Servant N; Alt M; Rouzier R; Paoletti X; Delattre O; Bièche I
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
